SCHEMBL21615892

SCHEMBL21615892

NC(=O)c1ccccc1C1(O)CCC(N)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
METAP2 P50579 1/20 0.37
BCAT2 O15382 1/20 0.36
OPRL1 P41146 1/20 0.36
TP53 P04637 1/20 0.35
PARP1 P09874 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
OPRM1 P35372 4/20 0.34
GAA P10253 1/20 0.33
CTNNB1 P35222 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3451774 0.75 KDM4E (0.42) PDK2KDM4EALDH1A1MAPTHPGD
SCHEMBL29065566 0.72 ALDH1A1 (0.38) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL3840448 0.70 KDM4E (0.45) PDK2KDM4EALDH1A1MAPTHPGD
SCHEMBL6659416 0.70 OPRL1 (0.56) ALDH1A1OPRL1OPRM1
SCHEMBL6659407 0.70 OPRL1 (0.56) ALDH1A1OPRL1OPRM1
SCHEMBL6659414 0.70 OPRL1 (0.56) ALDH1A1OPRL1OPRM1
SCHEMBL17786074 0.69 PDK2 (0.40) PDK2KDM4EALDH1A1MAPTHPGD
SCHEMBL11259349 0.69 OPRL1 (0.48) OPRL1OPRM1
SCHEMBL11233815 0.69 METAP2 (0.39) PDK2KDM4EALDH1A1MAPTHPGD
SCHEMBL7226244 0.68 PARP1 (0.50) PARP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4380575-A1 DRUG CONJUGATES OF SUGAR DERIVATIVES AND USES THEREOF AS SENOLYTIC AGENTS Rubedo Life Sciences, Inc. (US) 2024-06-12 EP disclosed
US-20230321130-A1 Senolytic Compositions and Uses Thereof Rubedo Life Sciences, Inc. 2023-10-12 US disclosed
US-20230137021-A1 Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents Rubedo Life Sciences, Inc. 2023-05-04 US disclosed
WO-2023039600-A1 DRUG CONJUGATES OF SUGAR DERIVATIVES AND USES THEREOF AS SENOLYTIC AGENTS Rubedo Life Sciences, Inc. (US) 2023-03-16 WO disclosed
US-20210299154-A1 Senolytic Compositions And Uses Thereof Rubedo Life Sciences, Inc. 2021-09-30 US disclosed
US-11026963-B2 Senolytic compositions and uses thereof Rubedo Life Sciences, Inc. (US) 2021-06-08 US disclosed
EP-3790861-A1 SENOLYTIC COMPOSITIONS AND USES THEREOF Rubedo Life Sciences, Inc. (US) 2021-03-17 EP disclosed
CN-112469697-A Anti-aging composition and application thereof 鲁贝多生命科学公司 2021-03-09 CN disclosed
US-20200016185-A1 SENOLYTIC COMPOSITIONS AND USES THEREOF Rubedo Life Sciences, Inc. 2020-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299154-A1 Senolytic Compositions And Uses Thereof SENP3, SENP6, SENP1 PDK2 405/4885KDM4E 4172/4885ALDH1A1 1807/4885
US-11026963-B2 Senolytic compositions and uses thereof SENP3, SENP6, SENP1 PDK2 405/4885KDM4E 4172/4885ALDH1A1 1807/4885
US-20200016185-A1 SENOLYTIC COMPOSITIONS AND USES THEREOF SENP3, SENP6, SENP1 PDK2 405/4885KDM4E 4172/4885ALDH1A1 1807/4885
US-20230137021-A1 Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents AGER, SENP6, SENP3 PDK2 131/4885KDM4E 3425/4885ALDH1A1 748/4885
US-20230321130-A1 Senolytic Compositions and Uses Thereof SENP3, SENP6, SENP1 PDK2 405/4885KDM4E 4172/4885ALDH1A1 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.